Publications by authors named "Ina Hagelschuer"
Article Synopsis
- - Chronic kidney disease (CKD) progression is linked to oxidative stress damaging the NO-sGC-cGMP signaling pathway, but runcaciguat is a new drug that can activate dysfunctional sGC and restore this signaling under such conditions.
- - In studies with ZSF1 rats (a model for CKD/DKD), runcaciguat significantly reduced proteinuria and improved kidney function compared to placebo over a 12-week period with varying doses.
- - The treatment also positively impacted metabolic markers, reducing high blood sugar levels (HbA1c), triglycerides, and cholesterol in obese ZSF1 rats, suggesting its potential as a kidney-protective treatment.
In vivo luminescent imaging technology was introduced in experimental life science research several years ago and has rapidly gained wide acceptance. By making use of this technology substantially more information can be gained from animal experiments than was previously possible. The concept of the 3Rs describes the aim to Refine, Reduce and Replace animal models in research.
View Article and Find Full Text PDFBAY 41-4109 is a member of a class of heteroaryl-pyrimidines that was recently identified as potent inhibitors of human hepatitis B virus (HBV) replication. We have investigated the antiviral activity of BAY 41-4109 (methyl (R)-4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-pyrimidine-5-carboxylate) in HBV-transgenic mice (Tg [HBV1.3 fsX(-)3'5']).
View Article and Find Full Text PDF